These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35530285)

  • 1. A novel score system for predicting conversion to no evidence of Disease (C-NED) in initially unresectable colorectal cancer liver metastases.
    Li W; Zhou J; Zhang T; Tai Y; Xu Y; Bai Y; Jiang Y; Lu Z; Li L; Huang J; Pan Z; Wu X; Peng J; Lin J
    Am J Cancer Res; 2022; 12(4):1648-1659. PubMed ID: 35530285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multidisciplinary approach to the diagnosis and treatment of patients with potentially resectable colorectal cancer liver metastasis: results of a multicenter study.
    Han L; Xue J; Wu X; Liang G; Wu Y; Guo F; Gao S; Sun G
    Ann Palliat Med; 2022 Feb; 11(2):717-729. PubMed ID: 35249349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic factors affecting the success of conversion chemotherapy in patients with unresectable liver metastases from initially colorectal cancer].
    Zhang WL; Zhou C; Deng YX; Hou ZL; Zhang LJ; Lin JZ; Pan ZZ; Lu ZH; Peng JH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jan; 25(1):56-62. PubMed ID: 35067035
    [No Abstract]   [Full Text] [Related]  

  • 4. Application of Tumor Burden Score for predicting conversion outcome in patients with initially unresectable colorectal liver metastases after first-line systemic therapy.
    Peng J; Liu Y; Li W; Lin Y; Sun H; Pan Z; Wu X; Fan W; Lin J
    Therap Adv Gastroenterol; 2021; 14():17562848211066206. PubMed ID: 34987612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating Efficacy of Conversion Therapy on Patients with Initially Unresectable Colorectal Cancer Liver Metastases by using MRI: Development of a Predictive Score.
    Liu J; Tang W; Ye L; Miao G; Zeng M; Liu L
    Acad Radiol; 2024 May; ():. PubMed ID: 38734578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylated ctDNA predicts early recurrence risk in patients undergoing resection of initially unresectable colorectal cancer liver metastases.
    Chen ZG; Ji XM; Xu YX; Fong WP; Liu XY; Liang JY; Tan Q; Wen L; Cai YY; Wang DS; Li YH
    Ther Adv Med Oncol; 2024; 16():17588359241230752. PubMed ID: 38425989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of total tumor volume reduction ratio in initially unresectable colorectal liver metastases after first-line systemic treatment.
    He J; Li W; Zhou J; Sun H; Zhou C; Liu Y; Quan T; Fan W; Pan Z; Lin J; Peng J
    Eur J Radiol; 2023 Aug; 165():110950. PubMed ID: 37437437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion therapy combined with individualized surgical treatment strategy improves survival in patients with colorectal cancer liver metastases.
    Ma R; Li T
    Int J Clin Exp Pathol; 2021; 14(3):314-321. PubMed ID: 33786148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of preoperative serum lactate dehydrogenase levels in patients underwent curative-intent hepatectomy for colorectal liver metastases: A two-center cohort study.
    Bai L; Lin ZY; Lu YX; Chen Q; Zhou H; Meng Q; Lin CP; Huang WL; Wan YL; Pan ZZ; Wang DS
    Cancer Med; 2021 Nov; 10(22):8005-8019. PubMed ID: 34636145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial.
    Hu H; Wang K; Huang M; Kang L; Wang W; Wang H; Qiu M; Lin R; Zhang H; Lan P; Wu X; Liu G; Wan Y; Liu M; Zhou Z; Huang Y; Li F; Zhang J; Cai Y; Ma T; Zhou J; Wang H; Ling J; Cai Y; Wu Z; Luo S; Ling L; Deng Y
    Oncologist; 2021 Jan; 26(1):e90-e98. PubMed ID: 33400355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deep radiomics-based fusion model for prediction of bevacizumab treatment response and outcome in patients with colorectal cancer liver metastases: a multicentre cohort study.
    Zhou S; Sun D; Mao W; Liu Y; Cen W; Ye L; Liang F; Xu J; Shi H; Ji Y; Wang L; Chang W
    EClinicalMedicine; 2023 Nov; 65():102271. PubMed ID: 37869523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
    DʼAngelica MI; Correa-Gallego C; Paty PB; Cercek A; Gewirtz AN; Chou JF; Capanu M; Kingham TP; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR; Kemeny N
    Ann Surg; 2015 Feb; 261(2):353-60. PubMed ID: 24646562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review.
    Bolhuis K; Kos M; van Oijen MGH; Swijnenburg RJ; Punt CJA
    Eur J Cancer; 2020 Dec; 141():225-238. PubMed ID: 33189037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term outcomes of patients undergoing hepatectomy for bilateral multiple colorectal liver metastases-a propensity score matching analysis].
    Bao Q; Wang K; Wang HW; Jin KM; Xing BC
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Oct; 23(10):976-983. PubMed ID: 33053993
    [No Abstract]   [Full Text] [Related]  

  • 15. Chemotherapy and targeted therapy for patients with initially unresectable colorectal liver metastases, focusing on conversion hepatectomy and long-term survival.
    Beppu T; Miyamoto Y; Sakamoto Y; Imai K; Nitta H; Hayashi H; Chikamoto A; Watanabe M; Ishiko T; Baba H
    Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S405-13. PubMed ID: 24570379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prognostic Scoring System to Predict Survival Outcome of Resectable Colorectal Liver Metastases in this Modern Era.
    Liu W; Zhang W; Xu Y; Li YH; Xing BC
    Ann Surg Oncol; 2021 Nov; 28(12):7709-7718. PubMed ID: 34023948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Evaluation of Relapse Risk (CERR) Score for Colorectal Liver Metastases: Development and Validation.
    Chen Y; Chang W; Ren L; Chen J; Tang W; Liu T; Jian M; Liu Y; Wei Y; Xu J
    Oncologist; 2020 Jul; 25(7):e1031-e1041. PubMed ID: 32181531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of a novel biomarker combining DNA ploidy and tumor burden score for initially resectable liver metastases from patients with colorectal cancer.
    Peng J; Li W; Fan W; Zhang R; Li X; Xiao B; Dong Y; Wan D; Pan Z; Lin J; Wu X
    Cancer Cell Int; 2021 Oct; 21(1):554. PubMed ID: 34688293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.
    Pak LM; Kemeny NE; Capanu M; Chou JF; Boucher T; Cercek A; Balachandran VP; Kingham TP; Allen PJ; DeMatteo RP; Jarnagin WR; D'Angelica MI
    J Surg Oncol; 2018 Mar; 117(4):634-643. PubMed ID: 29165816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
    Folprecht G; Gruenberger T; Bechstein W; Raab HR; Weitz J; Lordick F; Hartmann JT; Stoehlmacher-Williams J; Lang H; Trarbach T; Liersch T; Ockert D; Jaeger D; Steger U; Suedhoff T; Rentsch A; Köhne CH
    Ann Oncol; 2014 May; 25(5):1018-25. PubMed ID: 24585720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.